Spyre在200万美元的内部出售后倒闭

2026-06-24 22:39

Anti-inflammatory drug developer Spyre Therapeutics (SYRE) lost ~10% on Wednesday, potentially on track to record its biggest one-day decline in more than a year after its director, Michael Henderson, sold $2M worth of company stock.
The biotech executive sold 20K Spyre (SYE) shares for $100 apiece as part of a pre-arranged stock trading plan that complies with the SEC's insider trading rules, according to a regulatory filing on Tuesday.
His stake in Spyre (SYRE) fell 23% to roughly 68.6K shares after Monday’s transaction, the SEC filing indicated.
Henderson also serves as the CEO of Apogee Therapeutics (APGE), which agreed to be acquired by AbbVie (ABBV) in an all-cash deal worth $10.9B on Monday. Before that, he was the chief business officer at cardiology drug developer BridgeBio Pharma (BBIO).

More on Spyre Therapeutics